Positive impactCompany
AGES Austria issues GMP certification to Shilpa Medicare’s Jadcherla unit
CNBC-TV18 1 hr ago·10 Oct 2026, 8:53 am
Shilpa Medicare has received a crucial Good Manufacturing Practice (GMP) certification from AGES Austria for its Jadcherla unit. This recognition from a European authority signals that the facility meets high international standards for quality control and safety. Additionally, the company has obtained approval from the Central Drugs Standard Control Organisation (CDSCO) to market its OERIS chemotherapy anti-nausea injection within India.
This dual development is significant for investors as it expands the company's product portfolio and validates its manufacturing capabilities. GMP certification is often a prerequisite for exporting products globally, which can open new revenue streams. Furthermore, the approval for the specific chemotherapy injection strengthens Shilpa Medicare's position in the oncology segment.
Investors should watch for updates on the commercial launch of the OERIS injection and any future orders from international clients that may result from the new certification.
Excerpt from CNBC-TV18
Published On Oct 10, 2026 | 14:23 IST Last Updated On Oct 10, 2026 | 14:23 IST Shilpa Medicare received GMP certification for its Jadcherla unit from Austria's AGES. Additionally, the company secured SEC approval in India to market OERIS, an extended-release anti-nausea injection providing five-day protection for…Read the original at CNBC-TV18
Affected stocks
Bullish1 stock
Bull / bear label is derived from the article's AI sentiment — indicative, not advice. Prices may be delayed.
Key takeaways
- Concerns Shilpa Medicare (SHILPAMED).
- Category: Company.
- AI reads the tone as positive (potentially bullish) for the stock.
Why it matters
A routine update for Shilpa Medicare. The tone is positive — historically associated with upward pressure, though not predictive. Use the price and stock snapshot to gauge how the market is responding.
